Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Authors: Lei J,  Rudolph A,  Moysich KB,  Rafiq S,  Behrens S,  Goode EL,  Pharoah PP,  Seibold P,  Fasching PA,  Andrulis IL,  Kristensen VN,  Couch FJ,  Hamann U,  Hooning MJ,  Nevanlinna H,  Eilber U,  Bolla MK,  Dennis J,  Wang Q,  Lindblom A,  Mannermaa A,  Lambrechts D,  García-Closas M,  Hall P,  Chenevix-Trench G,  Shah M,  Luben R,  Haeberle L,  Ekici AB,  Beckmann MW,  Knight JA,  Glendon G,  Tchatchou S,  Alnæs GI,  Borresen-Dale AL,  Nord S,  Olson JE,  Hallberg E,  Vachon C,  Torres D,  Ulmer HU,  Rüdiger T,  Jager A,  van Deurzen CH,  Tilanus-Linthorst MM,  Muranen TA,  Aittomäki K,  Blomqvist C,  Margolin S,  Kosma VM,  Hartikainen JM,  Kataja V,  Hatse S,  Wildiers H,  Smeets A,  Figueroa J,  Chanock SJ,  Lissowska J,  Li J,  Humphreys K,  Phillips KA,  kConFab Investigators,  Linn S,  Cornelissen S,  van den Broek SA,  Kang D,  Choi JY,  Park SK,  Yoo KY,  Hsiung CN,  Wu PE,  Hou MF,  Shen CY,  Teo SH,  Taib NA,  Yip CH,  Ho GF,  Matsuo K,  Ito H,  Iwata H,  Tajima K,  Dunning AM,  Benitez J,  Czene K,  Sucheston LE,  Maishman T,  Tapper WJ,  Eccles D,  Easton DF,  Schmidt MK,  Chang-Claude J
Journal: Breast Cancer Res
Date: 2015
Branches: HREB, LTG, OD, OEEB
PubMed ID: 25849327
PMC ID: PMC4374346
Abstract: INTRODUCTION: Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative patients (1,499 treated with chemotherapy). METHODS: We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133 genes were genotyped as part of the Collaborative Oncological Gene-environment Study, in which phenotype and clinical data were collected and harmonized. Multivariable Cox proportional hazard regression was used to assess genetic associations with overall survival (OS) and breast cancer-specific survival (BCSS). Heterogeneity according to chemotherapy or ER status was evaluated with the log-likelihood ratio test. RESULTS: Three independent SNPs in TGFBR2 and IL12B were associated with OS (P <10⁻³) solely in ER-negative patients after chemotherapy (267 events). Poorer OS associated with TGFBR2 rs1367610 (G > C) (per allele hazard ratio (HR) 1.54 (95% confidence interval (CI) 1.22 to 1.95), P = 3.08 × 10⁻⁴) was not found in ER-negative patients without chemotherapy or ER-positive patients with chemotherapy (P for interaction <10-3). Two SNPs in IL12B (r² = 0.20) showed different associations with ER-negative disease after chemotherapy: rs2546892 (G > A) with poorer OS (HR 1.50 (95% CI 1.21 to 1.86), P = 1.81 × 10⁻⁴), and rs2853694 (A > C) with improved OS (HR 0.73 (95% CI 0.61 to 0.87), P = 3.67 × 10⁻⁴). Similar associations were observed with BCSS. Association with TGFBR2 rs1367610 but not IL12B variants replicated using BCAC Asian samples and the independent Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer Study and yielded a combined HR of 1.57 ((95% CI 1.28 to 1.94), P = 2.05 × 10⁻⁵) without study heterogeneity. CONCLUSIONS: TGFBR2 variants may have prognostic and predictive value in ER-negative breast cancer patients treated with adjuvant chemotherapy. Our findings provide further insights into the development of immunotherapeutic targets for ER-negative breast cancer.